Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Brain Cogn ; 43(1-3): 246-52, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-10857703

RESUMEN

Five hundred one right-handers (150 men, 351 women) and 53 left-handers (15 men, 38 women) were asked to imagine holding a young infant in their arms. Right-handers reported significant left-side biases--in 68% of the men and 73% of the women. For left-handers, side preferences were weaker, the left-side bias dropping to 47% for men and 60% for women, with neither figure different from chance. The results are discussed in the context of theory and research on the functional neuroanatomy of attention, emotional arousal, and the generation, maintenance, and manipulation of mental images.


Asunto(s)
Lateralidad Funcional/fisiología , Imaginación , Desempeño Psicomotor/fisiología , Adulto , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas , Factores Sexuales
2.
Am J Respir Cell Mol Biol ; 20(4): 658-66, 1999 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10100997

RESUMEN

Nitric oxide (NO) is an important mediator of physiologic processes in the airway. Levels of exhaled NO are greatest and asthma symptoms are least in menstruating women during midcycle, when estrogen levels are highest. To better understand the role of estrogen in airway function, we tested the hypothesis that estrogen stimulates endothelial NO synthase (eNOS) in NCI-H441 human bronchiolar epithelial cells. eNOS activation was assessed by measuring conversion of [3H]L-arginine to [3H]L-citrulline in intact cells. eNOS activity rose in the presence of estradiol-17beta (E2beta), with a maximum stimulation of 243% at 10(-8) M E2beta. This response was comparable to the 201% increase elicited by the calcium (Ca2+) ionophore A23187 (10(-5) M), and was evident as early as 5 min after such treatment. Actinomycin D had no effect on the response to E2beta, and eNOS abundance was similar in control and E2beta-treated cells. E2beta-stimulated eNOS activity was dependent on the influx of extracellular Ca2+, and was completely inhibited by the estrogen receptor (ER) antagonist ICI182,780. Messenger RNA and protein for the alpha isoform of ER (ERalpha) were evident in the H441 cells, and freshly isolated ovine airway epithelial cells also coexpressed eNOS and ERalpha. These findings indicate that estrogen acutely activates existing eNOS in H441 airway epithelial cells, through a process that involves the stimulation of epithelial ER and Ca2+ influx. This process may play a role in the hormonal modulation of airway function.


Asunto(s)
Bronquios/metabolismo , Células Epiteliales/metabolismo , Estradiol/farmacología , Óxido Nítrico Sintasa/metabolismo , Receptores de Estrógenos/genética , Animales , Arginina/metabolismo , Bronquios/citología , Calcimicina/farmacología , Línea Celular , Dactinomicina/farmacología , Activación Enzimática , Células Epiteliales/citología , Estradiol/análogos & derivados , Receptor alfa de Estrógeno , Femenino , Fulvestrant , Humanos , Cinética , Menstruación , Óxido Nítrico Sintasa de Tipo III , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Ovinos , Útero/metabolismo
3.
Lancet ; 350(9089): 1439-43, 1997 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-9371168

RESUMEN

BACKGROUND: Meningococcal sepsis remains an important cause of morbidity and mortality. We hypothesised that children with severe meningococcaemia might benefit from inhibition of the inflammatory processes thought responsible for fulminant disease. rBPI21 is a recombinant, N-terminal fragment of human bactericidal/permeability-increasing protein, which kills meningococci and binds to and clears bacterial endotoxin, these being the primary inducers of the systemic inflammation. The aim of this study was to determine the safety and kinetics of rBPI21 in children with severe meningococcaemia and to make a preliminary assessment of clinical outcome. METHODS: In this open-label, dose-escalation, phase I/II trial in severe meningococcaemia (Glasgow meningococcal prognostic septicaemia score [GMSPS] > or = 8), 26 patients aged 1-18 years, who had received their first dose of antibiotics no more than 8 hours earlier were given rBPI21 by infusion at total doses of 1.0, 2.0, and 4.0 mg/kg. FINDINGS: The patients had significantly raised plasma concentrations of bacterial endotoxin and cytokines. Peak and steady state BPI concentrations were comparable with pharmacokinetic data in healthy adults. All complications were compatible with the expected pattern for severe meningococcal sepsis. Only one patient died. This outcome was found to compare favourably with a predicted mortality of > or = 30% by GMSPS, > or = 15% by plasma endotoxin values, > or = 28% by plasma interleukin-6 concentrations, 29-49% by severity of coagulopathy, and 20% (11/54) by comparison with recent historical patients consecutively treated in participating centres before this study. INTERPRETATION: This, the first clinical trial or rBPI21, shows that rBPI21 can be safely administered to children with severe meningococcaemia and that the pharmacokinetics are consistent with patterns seen in healthy adults. Predicted mortality, on the basis of GMSPS, laboratory indices of inflammation and coagulopathy, and historical controls, was for between four and eight deaths. These findings have prompted a phase III randomised trial.


Asunto(s)
Antiinfecciosos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Proteínas Sanguíneas/uso terapéutico , Proteínas de la Membrana , Infecciones Meningocócicas/tratamiento farmacológico , Adulto , Antiinfecciosos/efectos adversos , Antiinfecciosos/farmacocinética , Péptidos Catiónicos Antimicrobianos , Bacteriemia/microbiología , Bacteriemia/mortalidad , Actividad Bactericida de la Sangre , Proteínas Sanguíneas/efectos adversos , Proteínas Sanguíneas/farmacocinética , Niño , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Infecciones Meningocócicas/mortalidad , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/uso terapéutico , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA